Exagen (XGN) falls 0.99% for September 14

Equities Staff  |

Exagen Inc (NASDAQ: XGN), a Vista, California, company, fell to close at $13.00 Tuesday after losing $0.13 (0.99%) on volume of 142,479 shares. The stock ranged from a high of $13.40 to a low of $12.73 while Exagen’s market cap now stands at $209,648,192.

About Exagen Inc

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on the proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen's goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.

Visit Exagen Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Exagen Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Exagen Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Cross Border Money Transfer Company Remitly Seeks $7 Billion IPO Valuation
Intuit To Acquire Mailchimp for $12 Billion in Cash and Stock
Consumer Brands Association Presses White House for More Clarity on Vaccine Mandates
Freshworks Shooting for $9 Billion IPO Valuation at Top End of Filing Range
Fauci Supports COVID-19 Vaccine Mandate for All Domestic Air Travel
Jobless Claims Fall to 310,000 — Lowest in Nearly 18 Months
200 Westerners Board Qatar Airways Flight From Kabul
Pennsylvania Republican Lawmakers Launch 'Election Integrity' Investigation



Market Movers

Sponsored Financial Content